Last updated: June 3, 2026
Technelite pharma drug: who are the suppliers and manufacturing sources?
No complete or consistent public record is available here to identify the drug “Technelite” with enough specificity to name suppliers, contract manufacturing organizations, or API/formulation sources.
What is Technelite and what active ingredient is it
A “Technelite” drug name is not uniquely identifiable to a single active ingredient, strength, dosage form, and FDA/NDA/BLA listing based on the information provided. Supplier identification for pharmaceuticals requires the exact product identity (active ingredient, route, strength, NDA/BLA, marketing authorization holder, and label).
What companies supply Technelite API and drug product
Supplier mapping depends on traceable product-level data:
- API manufacturer and site
- drug product (formulation, fill-finish) manufacturer and site
- labeled applicant/marketing authorization holder
- regulatory filings that list manufacturing sites (for example, FDA prescribing information, NDA supplements, or site inspection records)
No such product-specific identifiers are provided, so supplier names cannot be stated accurately.
Which CDMOs manufacture Technelite tablets, capsules, or injectables
CDMO identification requires at least one of:
- dosage form (tablet, capsule, suspension, injectable, etc.)
- strength(s)
- packaging type (bottle, blister, prefilled syringe, vial)
- application number and manufacturing section references
Without those, manufacturing-source attribution would be speculative.
What is the Orange Book status of Technelite
Orange Book status requires a specific FDA-approved drug listing (active ingredient + NDA holder). With no unique product match, Orange Book lookup cannot be performed to confirm listed patents, exclusivity, and manufacturing disclosures.
What patents protect Technelite and who owns them
Patent owners and listed assignees are tied to a specific FDA application and patent family. Without a unique Technelite identifier, an enforceable patent estate cannot be mapped to suppliers or manufacturing partners.
How do supplier and IP constraints affect generic or biosimilar entry
Generic and biosimilar entry risk depends on:
- listed patents and their expiration dates
- exclusivity periods
- formulation and method-of-use protections
- Paragraph IV history and litigation/settlement terms
None of these can be linked to “Technelite” without product identity.
Which regulatory pathway does Technelite use (NDA, ANDA, 505(b)(2))
Regulatory pathway classification requires the FDA application record for the specific active ingredient and dosage form. A general brand name alone is insufficient to determine pathway and supplier-linked submission history.
What generic entry risks exist for Technelite
Generic launch risk is driven by:
- patent landscape
- exclusivity
- approval history
- manufacturing readiness and label comparability
A supplier list cannot be produced without product-specific regulatory and patent data.
Key Takeaways
- “Technelite” is not uniquely identifiable from the information provided.
- Supplier, API, CDMO, and formulation source attribution for a pharmaceutical requires product-level identifiers (active ingredient, strength, dosage form, and FDA listing).
- No supplier list can be stated without risking incorrect identification.
FAQs
- How can I verify the API supplier for a specific drug brand name?
- Where do I find the contract manufacturer listed for a drug product?
- How do I map suppliers to FDA labeling and manufacturing site references?
- What Orange Book fields determine which company makes the product?
- How do patent owners correlate with manufacturing partnerships in licensing deals?
References
No sources were cited because no verifiable, product-specific Technelite record was established.
